keyword
MENU ▼
Read by QxMD icon Read
search

Prostatic specific antigen

keyword
https://www.readbyqxmd.com/read/28550496/prostate-cancer-in-jordanian-arab-population-erg-status-and-relationship-with-clinicopathologic-characteristics
#1
Najla Aldaoud, Nour Abdo, Samir Al Bashir, Mohammad Alqudah, Noor Marji, Hiba Alzou'bi, Rami Alazab, Kiril Trpkov
TMPRSS2/ERG fusion was found to be the most common genetic event in prostate adenocarcinoma. There is a strong correlation between the fusion and ERG-positive immunostaining. Many studies showed racial variation in ERG expression in prostate cancer patients. There is no data however on the rate of ERG-positive cancer in Jordanian or Arab population. We evaluated the frequency and the significance of ERG fusion in Jordanian-Arab population using immunohistochemistry for ERG. The cohort included 193 prostate cancer specimens: 109 needle core biopsies, 45 radical prostatectomies, 37 transurethral resections of prostate, and 2 enucleation specimens...
May 26, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28548924/comparing-the-clinical-efficacy-of-abiraterone-acetate-enzalutamide-and-orteronel-in-patients-with-metastatic-castration-resistant-prostate-cancer-by-performing-a-network-meta-analysis-of-eight-randomized-controlled-trials
#2
Minyong Kang, Chang Wook Jeong, Cheol Kwak, Ja Hyeon Ku, Hyeon Hoe Kim
Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable oncological outcomes. Here, we aimed to compare the efficacy of novel AR-targeted agents by performing a network meta-analysis of randomized controlled trials (RCTs). We included eight RCTs for men with mCRPC treated with one of the AR targeting agents: abiraterone acetate, enzalutamide, or orteronel...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28548372/initial-multicentre-experience-of-68-gallium-psma-pet-ct-guided-robot-assisted-salvage-lymphadenectomy-acceptable-safety-profile-but-oncological-benefit-appears-limited
#3
Amila Siriwardana, James Thompson, Pim J van Leeuwen, Shaela Doig, Anton Kalsbeek, Louise Emmett, Warick Delprado, David Wong, Hemamali Samaratunga, Anne-Maree Haynes, Geoff Coughlin, Phillip Stricker
OBJECTIVES: To evaluate the safety and short-term oncological outcomes for (68) Ga-PSMA PET/CT directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for (68) Ga-PSMA PET/CT detected oligometastatic nodal recurrence. RASND was performed by targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease...
May 26, 2017: BJU International
https://www.readbyqxmd.com/read/28546760/analysis-of-immune-status-after-iodine-125-permanent-brachytherapy-in-prostate-cancer
#4
E Du, Lin Wang, Chang-Ying Li, Chang-Wen Zhang, Yan-Chun Qu, Ran-Lu Liu, Yong Xu, Kuo Yang, Zhi-Hong Zhang
BACKGROUND: Permanent prostate brachytherapy (PPB) is an effective treatment choice for low and intermediate risk prostate cancer (PCa). However, the impact of PPB on tumor immune status is still poorly understood. This study aimed to assess the immune status in PCa patients before and at different time points after PPB (1, 3, 6, and 12 months). METHODS: Blood was collected from 32 patients with low and intermediate risk PCa and 12 healthy volunteers. The frequency of immunocompetent cells was identified by flow cytometry...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28546712/screening-and-detection-of-prostate-cancer-review-of-literature-and-current-perspective
#5
REVIEW
Ananthakrishnan Sivaraman, Kulthe Ramesh Seetharam Bhat
Screening of prostatic cancer is a matter of debate among uro-oncologist. With many new screening modalities like prostatic health index (PHI), 4K testing the role of screening has increased as one is able to stratify patients with serum prostate specific antigen level in a grey zone of 4-10 ng/ml and normal digital rectal examination into various risk groups, thus avoiding unnecessary biopsy which was the pitfalls of routine screening practice. PHI is better at predicting malignancy while 4K is better at predicting high-grade disease...
June 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28546332/establishing-177-lu-psma-617-radioligand-therapy-in-a-syngeneic-model-of-murine-prostate-cancer
#6
Wolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, Katharina Lückerath, Liu Wei, Woosuk Kim, Soumya Poddar, Jonathan Said, Caius G Radu, Matthias Eiber, Johannes Czernin, Roger Slavik, Ken Herrmann
Clinical (177)Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced stage prostate cancer. However, to the best of our knowledge murine models to study the biological effects of various activity levels have not been established. AIM: To optimize specific and total activity for (177)Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer. Methods: 0.1x106 murine reconstituted, oncogene-driven prostate cancer cells (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected into the left flank of C57Bl6 immunocompetent mice...
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28546330/exploring-new-multimodal-quantitative-imaging-indices-for-the-assessment-of-osseous-tumour-burden-in-prostate-cancer-using-68-ga-psma-pet-ct
#7
Marie Bieth, Markus Krönke, Robert Tauber, Marielena Dahlbender, Margitta Retz, Stephan G Nekolla, Bjoern Menze, Tobias Maurer, Matthias Eiber, Markus Schwaiger
Positron-emission-tomography (PET) combined with computed-tomography (CT) and prostate-specific-membrane-antigen (PSMA) ligands has gained significant interest for staging prostate cancer (PC). In this study, we propose two multimodal quantitative indices as imaging biomarker for the assessment of osseous tumour burden using (68)Ga-PSMA-PET/CT and present preliminary clinical data. We define two Bone-PET-Indices (BPI) that incorporate anatomical information from CT and functional information from (68)Ga-PSMA-PET: BPIVOL is the percental bone volume affected by tumour...
May 25, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28545997/factors-associated-with-survival-following-radium-223-treatment-for-metastatic-castration-resistant-prostate-cancer
#8
William W Wong, Eric M Anderson, Homan Mohammadi, Thomas B Daniels, Steve E Schild, Sameer R Keole, C Richard Choo, Katherine S Tzou, Alan H Bryce, Thai H Ho, Fernando J Quevedo, Sujay A Vora
BACKGROUND: Radium-223 ((223)Ra) improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This retrospective analysis was performed to better understand its efficacy in routine clinical practice and identify factors associated with survival. MATERIALS AND METHODS: Sixty-four patients with mCRPC who received (223)Ra between 2013 and 2015 were the basis of this retrospective study. Clinical outcomes and patient characteristics were obtained...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28545199/cyberknife-radioablation-of-prostate-cancer-%C3%A2-preliminary-results-for-400-patients
#9
Leszek Miszczyk, Agnieszka Namysł Kaletka, Aleksandra Napieralska, Grzegorz Woźniak, Małgorzata Stąpór Fudzińska, Grzegorz Głowacki, Andrzej Tukiendorf
Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28542476/functional-interaction-between-co-expressed-mage-a-proteins
#10
Julieta E Laiseca, María F Ladelfa, Javier Cotignola, Leticia Y Peche, Franco A Pascucci, Bryan A Castaño, Mario D Galigniana, Claudio Schneider, Martin Monte
MAGE-A (Melanoma Antigen Genes-A) are tumor-associated proteins with expression in a broad spectrum of human tumors and normal germ cells. MAGE-A gene expression and function are being increasingly investigated to better understand the mechanisms by which MAGE proteins collaborate in tumorigenesis and whether their detection could be useful for disease prognosis purposes. Alterations in epigenetic mechanisms involved in MAGE gene silencing cause their frequent co-expression in tumor cells. Here, we have analyzed the effect of MAGE-A gene co-expression and our results suggest that MageA6 can potentiate the androgen receptor (AR) co-activation function of MageA11...
2017: PloS One
https://www.readbyqxmd.com/read/28540788/salvage-focal-cryosurgery-may-delay-use-of-androgen-deprivation-therapy-in-cryotherapy-and-radiation-recurrent-prostate-cancer-patients
#11
Michael Kongnyuy, Courtney J Berg, Kaitlin E Kosinski, David J Habibian, Jeffrey T Schiff, Anthony T Corcoran, Aaron E Katz
INTRODUCTION: Salvage treatment options for recurrent unilateral prostate cancer (PCa) after primary radiation are limited and associated with severe complications and poor quality of life measures. Salvage focal cryotherapy (SFC) has shown success in biochemical recurrence (BCR) free survival. We aim to determine if SFC can delay use of androgen deprivation therapy (ADT) in recurrent PCa with low morbidity. METHODS: A retrospective review of patients who underwent SFC at our institution from 2007 to 2015 was performed...
March 29, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28539853/treatment-of-cancer-and-inflammation-with-low-dose-ionizing-radiation-three-case-reports
#12
Shuji Kojima, Mitsutoshi Tsukimoto, Noriko Shimura, Hironobu Koga, Akishisa Murata, Tsuyoshi Takara
There is considerable evidence from experimental studies in animals, as well as from clinical reports, that low-dose radiation hormesis is effective for the treatment of cancer and ulcerative colitis. In this study, we present 3 case reports that support the clinical efficacy of low-dose radiation hormesis in patients with these diseases. First, a patient with prostate cancer who had undergone surgical resection showed a subsequent increase in prostate-specific antigen (PSA). His PSA value started decreasing immediately after the start of repeated low-dose X-ray irradiation treatment and remained low thereafter...
January 2017: Dose-response: a Publication of International Hormesis Society
https://www.readbyqxmd.com/read/28537896/5t4-oncofoetal-glycoprotein-an-old-target-for-a-novel-prostate-cancer-immunotherapy
#13
Federica Cappuccini, Emily Pollock, Stephen Stribbling, Adrian V S Hill, Irina Redchenko
The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attributable primarily to CD8+ T cells...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28536833/development-of-standardized-image-interpretation-for-68ga-psma-pet-ct-to-detect-prostate-cancer-recurrent-lesions
#14
Stefano Fanti, Silvia Minozzi, Joshua James Morigi, Frederik Giesel, Francesco Ceci, Christian Uprimny, Michael S Hofman, Matthias Eiber, Sarah Schwarzenbock, Paolo Castellucci, Cristina Bellisario, Stéphane Chauvie, Fabrizio Bergesio, Louise Emmett, Uwe Haberkorn, Irene Virgolini, Markus Schwaiger, Rodney J Hicks, Bernd J Krause, Arturo Chiti
METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence...
May 23, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28535948/the-new-us-preventive-services-task-force-c-draft-recommendation-for-prostate-cancer-screening
#15
EDITORIAL
Matthew R Cooperberg
The US Preventive Services Task Force has issued a new draft guideline, with a "C" recommendation that men aged 55-69 yr should be informed about the benefits and harms of screening for prostate cancer, and offered prostate-specific antigen testing if they choose it. For men aged ≥70 yr, the recommendation remains "D", or "do not screen." This draft represents substantial progress in the right direction towards offering men a fair opportunity to discuss the risks and benefits of screening with their primary care providers...
May 20, 2017: European Urology
https://www.readbyqxmd.com/read/28534214/repeatability-of-68-ga-dkfz11-psma-pet-scans-for-detecting-prostate-specific-membrane-antigen-positive-prostate-cancer
#16
Joseph R Osborne, Teja M Kalidindi, Blesida J Punzalan, Kishore Gangangari, Daniel E Spratt, Wolfgang A Weber, Steven M Larson, Naga Vara Kishore Pillarsetty
PURPOSE: We studied the effect of varying specific activity of [(68)Ga]DKFZ-PSMA11 ([(68)Ga]DP11) on repeated imaging of prostate-specific membrane antigen-positive (PSMA+) xenograft tumors. PROCEDURES: Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA-) bilateral flank tumors were assessed to study intra- and inter-day repeatability of [(68)Ga]DP11 imaging in mice administered [(68)Ga]DP11 or [(67)Ga]DP11 (as a dilution tracer) using imaging and biodistribution studies...
May 22, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28533936/synthesis-and-evaluation-of-64-cu-psma-617-targeted-for-prostate-specific-membrane-antigen-in-prostate-cancer
#17
Can Cui, Masayuki Hanyu, Akiko Hatori, Yiding Zhang, Lin Xie, Tomoya Ohya, Masami Fukada, Hisashi Suzuki, Kotaro Nagatsu, Cuiping Jiang, Rui Luo, Guoqiang Shao, Mingrong Zhang, Feng Wang
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 ((64)Cu), to evaluate the metabolism, biodistribution, and potential of [(64)Cu]PSMA-617 for PET imaging of prostate cancer. [(64)Cu]PSMA-617 was synthesized by heating PSMA-617 with [(64)Cu]CuCl2 in buffer solution at 90°C for 5 min. In vitro uptake was determined in two cell lines of prostate cancer. In vivo regional distributions were determined in normal and tumor-bearing mice. High radiolabeling efficiency of (64)Cu for PSMA-617 yielded [(64)Cu]PSMA-617 with >99% radiochemical purity...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28533796/parameters-predicting-for-prostate-specific-antigen-response-rates-at-one-year-post-low-dose-rate-intraoperative-prostate-brachytherapy
#18
Kevin Martell, Tyler Meyer, Michael Sia, Steve Angyalfi, Siraj Husain
PURPOSE: To develop a model for prostate specific antigen (PSA) values at one year among patients treated with intraoperatively planned (125)I prostate brachytherapy (IOPB). MATERIAL AND METHODS: Four hundred and deven patients treated with IOPB for prostate adenocarcinoma were divided into four groups: those with PSA values ≥ 3 ng/ml; < 3 and ≥ 2; < 2 and ≥ 1 or PSA < 1 between 10.5 and 14.5 months post implantation (1yPSA). Ordinal regression analysis was then performed between patient, tumor, and treatment characteristics...
April 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28533654/psma-expression-in-multinodular-thyroid-neoplasm-on-simultaneous-ga-68-psma-pet-mri
#19
Amarnath Jena, Shuaib Zaidi, Vikas Kashyap, Abhishek Jha, Sangeeta Taneja
PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI. The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted USG-guided FNAC which revealed Hurthle cell neoplasm. Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533638/clinical-utility-of-gallium-68-psma-pet-ct-scan-for-prostate-cancer
#20
Kumaraswamy G Kallur, Prashanth G Ramachandra, Krishnappa Rajkumar, Shivakumar S Swamy, Indiresh Desai, Raghavendra M Rao, Shekhar Gowda Patil, P S Sridhar, Nagaraj Madhusudhan, Raghunath S Krishnappa, Veerendra Bhadrasetty, Hemantha M Kumara, S D Santhosh, Basavalingaiah S Ajaikumar
BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
keyword
keyword
25552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"